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mutations in the ﬁbrinogen A alpha chain (FGA) gene, and it is the most common cause of hereditary renal
amyloidosis in the UK. Patients typically present with kidney impairment and progress to end-stage renal
disease over a median time of 4.6 years.
Methods: Six patients presented with proteinuria, hypertension, and/or lower limb edema and underwent
detailed clinical and laboratory investigations.
Results: A novel FGA gene mutation was identiﬁed in each case: 2 frameshift mutations F521Sfs*27
and G519Efs*30 and 4 single base substitutions G555F, E526K, E524K, R554H. In 5 subjects,
extensive amyloid deposits were found solely within the glomeruli, which stained speciﬁcally
with antibodies to ﬁbrinogen A alpha chain, and in one of these cases, we found coexistent
ﬁbrinogen A alpha chain amyloidosis and anti-glomerular basement membrane antibody disease.
One patient was diagnosed with light-chain amyloidosis after a bone marrow examination revealed
a small clonal plasma cell population, and laser microdissection of the amyloid deposits followed by
liquid chromatography and tandem mass spectrometry identiﬁed kappa light chain as the ﬁbril
protein.
Discussion: We report 6 novel mutations in the FGA gene: 5 were associated with renal ﬁbrinogen A
alpha chain amyloidosis and 1 was found to be incidental to light-chain amyloid deposits discovered in a
patient with a plasma cell dyscrasia. Clinical awareness and suspicion of hereditary amyloidosis
corroborated by genetic analysis and adequate typing using combined immunohistochemistry and laser
microdissection and mass spectrometry is valuable to avoid misdiagnosis, especially when a family
history of amyloidosis is absent.
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International Reports (2017) 2, 461–469A myloidosis is a disorder of protein folding char-acterized by conformational change of native
globular proteins into ﬁbrils with a beta-sheet appear-
ance. The deposition of amyloid ﬁbrils in an extracel-
lular space readily leads to progressive disruption of
the structure and function of affected tissues and461
Table 1. Commercial antisera used in immunohistochemistry
Antibody to identify Raised in Working dilution Source
P-component Rabbit 1:200 DAKO
AA (REU 86.2) Mouse 1:100 Euro Diagnostica
Kappa Rabbit 1:20,000 DAKO
Lambda Rabbit 1:20,000 DAKO
Lysozyme Rabbit 1:1000 DAKO
Fibronogen alpha chain Sheep 1:300 Cambichem
apoA1 Goat 1:4000 Genzyme
Lect2 Goat 1:600 R&D Systems
TRANSLATIONAL RESEARCH D Rowczenio et al.: Fibrinogen A Alpha Chain Amyloidosisorgans.1 A growing number of proteins have been
implicated in systemic amyloidosis resulting in sub-
stantial disease heterogeneity; virtually any organ or
combination of organs other than the brain may be
affected by amyloid.
Hereditary renal amyloidosis is associated with
genetically altered proteins encoded by 7 genes:
ﬁbrinogen A alpha chain (FGA),2–6 apolipoprotein A1
(APOA1),7–18 apolipoprotein A2 (APOA2),19 lysozyme
(LYZ),20,21 gelsolin (GSN),22–25 apolipoprotein C2
(APOC2),26 and apolipoprotein C3 (APOC3).27
Although the clinical syndromes caused by mutations
in these genes might vary with respect to the age at
disease onset, rate of progression, prognosis, and organ
involvement, patients typically present with protein-
uria and/or hypertension and progress to end-stage
renal disease (ESRD). Apolipoprotein A-I amyloidosis
may also present with cardiomyopathy, gastrointestinal
involvement, polyneuropathy, and skin and laryngeal
amyloid deposition. Lysozyme amyloidosis can be
associated with substantial accumulation of amyloid
within the liver and gastrointestinal tract, and gelsolin
amyloidosis typically causes cranial neuropathy.
The natural history of the renal decline to ESRD in
hereditary ﬁbrinogen A alpha chain (AFib) amyloidosis
is approximately 4.6 years from the onset of symptoms
and is much faster than in hereditary apolipoprotein
A–I amyloidosis where the median time is approxi-
mately 8 years,28 but substantially slower than in un-
treated systemic light-chain (AL) amyloidosis. To date,
9 mutations in the ﬁbrinogen A alpha chain gene (FGA,
GenBank accession no. NW_922217) have been
described and all, except the E526V variant that is
reported largely in Northern Europeans, were found
only in isolated kindreds from various parts of the
world. Kidney biopsies from all subjects with AFib
amyloidosis show a characteristic histological appear-
ance with striking glomerular enlargement and almost
complete obliteration of the normal architecture by
amyloid deposition with little or no vascular or inter-
stitial amyloid deposits.
Here we report 6 novel mutations in the FGA gene: 5
were associated with renal AFib amyloidosis and 1 was
found to be incidental to AL amyloid deposits discov-
ered in a patient with a plasma cell dyscrasia. The
clinical phenotypes associated with the novel FGA
mutations are described in detail.
METHODS
Patients
Six unrelated patients were presented with proteinuria
and were subsequently discovered to have amyloid
deposits on kidney biopsy: a 51-year-old Norwegian
man (patient 1), a 30-year-old North African woman462(patient 2), a 43-year-old French woman (patient 3), an
80-year-old Russian man (patient 4), a 69-year-old
Scottish man (patient 5), and a 68-year-old British
woman (subject 6). They underwent detailed clinical
evaluation as well as electrocardiography, echocardi-
ography, blood and urine biochemistry including a
search for a monoclonal protein by immunoﬁxation
electrophoresis of serum and urine, and serum free
light chains. Patients 1 and 6, both of whom were
assessed at the UK National Amyloidosis Centre, un-
derwent whole-body 123I-labeled serum amyloid P
component (SAP) scintigraphy.
Informed consent was obtained from all patients and
clinical care was in accordance with the Declaration of
Helsinki.
Histology and Immunohistochemistry
Renal biopsies from patients 1 and 2 were initially
examined at the Oslo University Hospital and subse-
quently restained at the UK National Amyloidosis
Centre. Biopsies frompatients 3 to 6were examined at the
UK National Amyloidosis Centre. Brieﬂy, 6-mm-thick
sections from formalin ﬁxed parafﬁn-embedded renal
biopsies were stained for amyloid with Congo red and
viewed under crossed polarized light. Immunohisto-
chemical staining of the amyloid deposits was performed
using a panel of monospeciﬁc antibodies speciﬁed in
Table 1, and as previously described.29 Speciﬁcity of
staining was conﬁrmed by prior absorption of the anti-
serum with pure antigen in each case, and positive
and negative controls were included in each run.
Laser Microdissection and Tandem Mass
Spectrometry
Laser microdissection (LMD) was performed on
Congo red-positive glomeruli as previously
described.30 The samples were digested and analyzed
by liquid chromatography and tandem mass spec-
trometry (LC-MS/MS) on a Thermo Velos Orbitrap
instrument or using an EASY-nanoLC (Proxeon;
Thermo-Scientiﬁc, Hemel Hempstead, UK) coupled to
HCTultra ETDII (Bruker Daltonics, Bruker UK
Limited, Coventry, UK). MS data ﬁles were analyzed
using Mascot31 (www.martixscience.com) to searchKidney International Reports (2017) 2, 461–469
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Biotechnology Information database. All positive
samples were further examined using an expanded
Swissprot database containing the 9 previously re-
ported FGA variants.
Genetic Investigations
Genomic DNA was extracted from whole blood treated
with ethylenediamine tetraacetic acid as previously
described.32 Exon 5 of the ﬁbrinogen A alpha chain gene
(FGA, GenBank accession no. NW_922217) was ampli-
ﬁed by polymerase chain reaction assay and analyzed by
automated sequencing with the polymerase chain reac-
tionprimers: forward50-GCTCTGTATCTGGTAGTACT-30
and reverse 50-ATCGGCTTCACTTCCGGC-30, and the
sequencing primer: 50-TGGGGCACATTTGAAGAG-30
and other solutions and cycling conditions that have
previously been described.33 The electropherograms of
the FGA gene were analyzed on the ABI 3130xl Genetic
Analyzer using SequencingAnalysis Software version 5.4.
Ampliﬁed DNA from patients 1 and 2 was cloned
to determine whether a single or both alleles of the
FGA gene were mutated. Brieﬂy, puriﬁed polymer-
ase chain reaction products were ligated to the
pGEM-T Easy Vector System (Promega) and trans-
formed into Escherichia coli NEB 5-alpha (New
England Biolabs) according to the manufacturer’s
instructions. Plasmid DNA was extracted from 24
independent clones using a QIAprep Spin MiniPrep
Kit (Qiagen) and the inserted fragment was excisedTable 2. Clinical symptoms and laboratory ﬁndings in the 6 patients with
Patient
number
Sex/age at
presentation/family
history Ethnicity Clinical symptoms
Base
(g
creatin
(ml/m
1 Male/48/no Norwegian Lower limb edema, hypertension,
nephrotic-range proteinuria, gradual
decline of renal function
2 Female/28/no North African Proteinuria diagnosed in early
pregnancy progressed to
nephrotic range. Slow
decline in renal function resulted
in hemodialysis
1
3 Female/41/yes on
maternal side
French Progressive nephrotic syndrome,
lower limb edema, high blood pressure
4 Male/70/no Russian 10-yr history of renal insufﬁciency, dialysis
5 Male/69/no Scottish Hemoproteinuria and advanced
CKD after a short history of
general malaise, high titer anti-GBM
antibodies, rapid decline in renal
function, dialysis
3
6 Female/68/no British Heavy proteinuria, history of recurrent
urinary tract infection, renal dysfunction
4
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; GBM, glomerular bas
Kidney International Reports (2017) 2, 461–469by restriction with EcoRI, gel puriﬁed and directly
sequenced.
To exclude other hereditary renal amyloidoses, the
APOA1, APOA2, and LYZ genes were sequenced in all
6 patients with the use of primers and reagents
described elsewhere.7,19,20
RESULTS
Clinical Findings
Clinical symptoms and laboratory ﬁndings in the 6
patients with renal impairement are shown in Table 2.
Patient 1 presented with a lower limb edema and hy-
pertension. Blood pressure was 149/106 mm Hg and the
remaining cardiorespiratory examination was within
normal limits. Investigations showed normal blood
count and clotting proﬁle. The patient had nephrotic-
range proteinuria of 7.4 g per 24 hours, urine
albumin-to-creatinine ratio 556 mg/mmol, serum
creatinine 134 mmol/l, and estimated glomerular ﬁltra-
tion rate (eGFR) 50 ml/min per 1.73 m2. There was no
evidence of a monoclonal protein and no evidence of
cardiac amyloid inﬁltration. SAP scintigraphy showed
isolated, but intense renal uptake. His renal function
had gradually declined, and 4 years after diagnosis, his
creatinine was 323 mmol/l with eGFR 18 ml/min
per 1.73 m2 and urine albumin-to-creatinine ratio 316
mg/mmol.
Patient 2 presented with proteinuria diagnosed in
early pregnancy,which progressed to nephrotic range in
the third trimester and persisted after delivery.renal impairement
line proteinuria
/24 h)/serum
ine (mmol/l)/eGFR
in per 1.73 m2)
Histology ﬁndings on a renal
biopsy in patients 1--5
and in patient 6 on
both renal and bone
marrow trephine
(bmt) biopsies FGA gene mutation
7.4/134/50 Amyloid deposits localized
uniquely within the glomeruli
G5555F
(p.G574F)
c.1720_1721delGGinsTT
.8/74/>60 Amyloid deposits localized
uniquely within
the glomeruli
F521Sfs*27
(p.F540Sfs*27)
c.1619_1622delTTGT
5.3/141/35 Amyloid deposits localized
uniquely within the glomeruli
G519Efs*30
(p.G538E*30)
c.1611delA
6.3/438/12 Amyloid deposits localized uniquely
within the glomeruli
E526K (p.E545K)
c.1627G>A
.2/400/<15 Amyloid deposits localized
uniquely within the glomeruli;
in addition, linear deposition
of anti-GBM antibodies was detected
E524K (p.E543K)
c.1633G>A
.3/49/>90 Amyloid deposits in the glomeruli
and in the vessels. In addition,
bmt revealed amyloid with no
immunospeciﬁc staining
R554H (p.R573H)
c.1718G>A
(nonamyloidogenic)
ement membrane.
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tuberculosis. She was normotensive. Initial in-
vestigations revealed normal blood count and clotting
proﬁle, proteinuria of 1.8 g per 24 hours, urine albumin-
to-creatinine ratio 117 mg/mmol, serum creatinine 74
mmol/l, and eGFR > 60 ml/min per 1.73 m2. Electrocar-
diography and echocardigraphy were normal, and there
was no evidence of a monoclonal protein. Her renal
function slowly declined over the following 3 years,
with a more rapid decline during and after her next
pregnancy, when she developed nephrotic-range pro-
teinuria and exacerbation of hypertension. Four years
after diagnosis, she started hemodialysis.
Patient 3 presented with nephrotic syndrome. On
direct questioning, the patient revealed a 2-year history
of hypertension and an extensive family history of renal
disease. Her mother and maternal grandmother were
both diagnosed with proteinuric nephropathy of un-
known origin and died at the age of 45 and 57 years,
respectively. The mother underwent renal trans-
plantation at the age of 43 years, but died with a func-
tioning renal allograft from sepsis 2 years later. The
patient’s physical examination showed a blood pressure
of 180/80 mm Hg and pitting lower limb edema. In-
vestigations revealed serum creatinine of 141 mmol/l,
eGFR 35 ml/min per 1.73 m2, proteinuria 5.3 g per 24
hours, and serum albumin 36 g/l. There was no evidence
of a monoclonal protein in serum or urine. Abdominal
ultrasound showed normal sized hyperechoic kidneys
and no other abdominal organomegaly. Echocardiogra-
phy revealed no signs of cardiac amyloidosis.
Patient 4 presented with proteinuria and a 10-year
history of renal insufﬁciency. He was normotensive
and physical examination was unremarkable except for
edema of the lower extremities. There was no evidence
of a monoclonal protein in serum or urine. Baseline
investigations showed normal clotting proﬁle, pro-
teinuria of 6.3 g per 24 hours, creatinine 438 mmol/l,
and eGFR 12 ml/min per 1.73 m2, and there was no
evidence of cardiac amyloidosis. Six months after
diagnosis, the patient commenced dialysis.
Patient 5 presented with hemoproteinuria and
advanced chronic kidney disease after a short history
of general malaise. Baseline investigations showed
normal full blood count and clotting screen, eGFR <15
ml/min per 1.73 m2, and normal C reactive protein. He
was noted to have high titer anti-glomerular basement
membrane (anti-GBM) antibodies (>500) and after a
kidney biopsy was diagnosed with anti-GBM antibody
disease, for which he received plasma exchange, ste-
roids, and cyclophosphamide. He was dialysed during
his therapy and did not regain dialysis independence.
Patient 6 was found incidentally to have protein-
uria. She denied symptoms of peripheral edema, and464did not have symptoms of cardiac or other organ
dysfunction. She was normotensive. Baseline in-
vestigations showed normal blood count and clotting
proﬁle, proteinuria of 4.3 g per 24 hours, creatinine 49
mmol/l, eGFR >90 ml/min per 1.73 m2, and normal
serum free light chains: kappa 19.1 mg/l, lambda 8.3
mg/l, K/L ratio 2.30. There was a 4 g/l IgG kappa
paraproteinemia, and bone marrow examination
revealed a low-level CD56 positive plasma cell popu-
lation (<10%). There was no evidence of cardiac
amyloidosis. SAP scintigraphy showed a large amyloid
load in the liver, spleen, kidneys, adrenals, and avid
uptake in the bones.
Histology and Immunohistochemistry
Extensive amyloid deposits were identiﬁed on the
kidney biopsies of patients 1 to 4 by their patho-
gnomonic green birefringence when stained with
Congo red and viewed under crossed polarized light
(Figure 1a and b). The deposits were localized
exclusively in the glomeruli resulting in striking
glomerular enlargement with almost complete oblit-
eration of the normal glomerular architecture. There
was no amyloid within the tubules, interstitium, or
vessels. The amyloid stained speciﬁcally with anti-
bodies to ﬁbrinogen A alpha chain (Figure 1c), and
staining was completely abolished by prior absorp-
tion of the antiserum with an excess of pure human
ﬁbrinogen A alpha chain. The antibody that was used
could detect the wild-type (WT) and mutant AFib
peptide, the latter resulting from either a single amino
acid substitution or the frameshift mutations. There
was no staining of the amyloid with the remaining
antibodies listed in the Methods. In patient 5, in
addition to extensive amyloid, localized uniquely
within the glomeruli that stained speciﬁcally with
antibodies to ﬁbrinogen A alpha chain, the kidney
biopsy showed crescentic glomerulonephritis with
the involvement of 7 of 15 glomeruli. Immunoﬂuo-
rescence microscopy showed linear deposition of anti-
GBM antibodies.
In patient 6, the kidney biopsy revealed Congo red-
positive staining in the glomeruli and the vessels, but
the immunohistochemistry did not show any immuno-
speciﬁc staining and was therefore inconclusive. Congo
red staining of the bone marrow trephine in this patient
also revealed amyloid with no immunospeciﬁc staining.
FGA Gene Analysis
A novel FGA gene mutation was identiﬁed in each case
(Figure 2). Patient 1 had 2 consecutive guanine bases
deleted and 2 thymine bases inserted in their position.
Cloning of the polymerase chain reaction products
revealed that a single allele was affectedKidney International Reports (2017) 2, 461–469
Figure 1. Renal biopsy from patient 3 with a novel FGA mutation. Striking glomerular enlargement and almost complete obliteration of the
normal architecture by amyloid deposition is shown when (a) stained with Congo red and viewed using brightfield illumination, (b) stained with
Congo red and viewed under crossed polarized light, and (c) immunostained with antibodies to fibrinogen A alpha chain. For comparison, a
renal biopsy from a patient with kappa light-chain (AL) amyloidosis is shown; (d), (e) extensive amyloid is visible within glomeruli, (f) but there is
no staining above the background of the amyloid deposits with an antibody against fibrinogen A alpha chain.
D Rowczenio et al.: Fibrinogen A Alpha Chain Amyloidosis TRANSLATIONAL RESEARCH(c.1720_1721delGGinsTT), resulting in a substitution
of glycine with phenylalanine at position 555 of the
mature protein (p.G574F; this nomenclature includes
19-amino-acid signal peptide) (Figure 2a). Two novel
frameshift mutations F521Sfs*27 (p.F540Sfs*27), result-
ing from deletion of 4 consecutive nucleotides
(c.1619_1622delTTGT), and G519Efs*30 (p.G538E*30),
resulting from a deletion of an adenine nucleotide
(c.1611delA), were found in patients 2 and 3, respec-
tively (Figure 2b and c). The new reading frame
created by each deletion predicted the premature
termination of the protein 27 and 30 amino acids
downstream from the site of mutation. Three single
base substitutions (c.1627G>A), (c.1633G>A), and
(c.1718G>A) were identiﬁed in patients 4, 5, and 6,
respectively, replacing glutamic acid with lysine at
codons 526 (p.E545K) and 524 (p.E543K) and arginine
with histidine at position 554 (p.R573H) (Figure 2d–f).
There was no mutation in other genes known to be
associated with renal amyloidosis including APOA1,
APOA2, and LYZ.
Laser Microdissection and Mass Spectrometry
LMD followed by LC-MS/MS proteomics analysis was
undertaken on samples from patients 1 and 2 in OsloKidney International Reports (2017) 2, 461–469and patients 1, 3, 4, 5, and 6 in London. Amyloid
signature proteins (SAP, ApoE, or ApoA4) were
detected in the amyloid deposits of all patients.
Fibrinogen A alpha chain was identiﬁed in patients 1 to
5 conﬁrming AFib amyloidosis. In patient 6, only
kappa light chains were evident and ﬁbrinogen was
absent; this patient was diagnosed with AL
amyloidosis.
Data from patients 1, 4, and 5 were further analyzed
using the extended FibA database. It was not possible
to conﬁrm the presence of the variant G555F (p.G574F)
in patient 1 because the putative variant tryptic pep-
tide could not be observed due to its very low molec-
ular mass; however, the peptide coverage was entirely
consistent with that observed in other cases of AFib
amyloidosis other than the absence of the correspond-
ing WT peptide. Variant E526K (p.E545K) was present
in amyloid from patient 4 with 2 peptides identiﬁed,
p.528-545 and p.546-558, covering the new tryptic
cleavage site. Variant E524K (p.E543K) was identiﬁed in
patient 5 by the presence of a new tryptic peptide:
p.528-543. Assignments were conﬁrmed by manual
sequencing of MS/MS spectra for the relevant tryptic
peptides. In both cases, there was evidence for the
corresponding WT peptide.465
Figure 2. Partial DNA sequence of exon 5 of the FGA gene showing 6 novel variants. (a) Results from patient 1. Top panel shows that 2
consecutive nucleotides GG are replaced by TT; cloning revealed that a single allele was mutated (c.1720_1721delGGinsTT) and the other allele
was wild type, shown in the middle and bottom panels, respectively. (b) Results from patient 2. Overlapping nucleotides on the electrophe-
rogram indicate a frameshift mutation; cloning revealed that a single allele had 4 nucleotides deleted (c.1619_1622delTTGT), and the other allele
was wild type, shown in the middle and bottom panels, respectively. (c) A deletion of an adenine nucleotide (c.1611delA) found in patient 3
resulted in a frameshift mutation. (d–f) A single base substitution: (c.1633G>A), (c.1627G>A), and (c.1718G>A) were identified in patients 4, 5,
and 6, respectively.
TRANSLATIONAL RESEARCH D Rowczenio et al.: Fibrinogen A Alpha Chain AmyloidosisThe MS/MS spectra of the frameshift variants were
examined manually. Variant F521Sfs*27 (p.F540Sfs*27)
was conﬁrmed in patient 2 by the identiﬁcation of a
new tryptic peptide, p.543-557, with MH2þ at m/z
793.97, and good sequence coverage (shown under-
lined) LSLGAQNLASSQIQR (Table 3). VariantTable 3. Identiﬁcation of frameshift mutations in ﬁbrinogen A alpha
chain peptide by tandem mass spectrometry-based proteomics
WT
p. 521-583
DTASTGKTFP GFFSPMLGEF VSETESRGSE
SGIFTNTKES SSHHPGIAEF PSRGKSSSYS KQF.......
p.F540Sfs*27
p.521-565
DTASTGKTFP GFFSPMLGES VRLSLGAQNL ASSQIQRNPV
LITLG
p.G538Efs*30
p.521-566
DTASTGKTFP GFFSPMLESL SVRLSLGAQN LASSQIQRNP
VLITLG
The C-terminal fragment of wild-type (WT) FibA alpha chain (p.521-583) is compared
with the C termini (p.521 end) of 2 frameshift variants, p.F540Sfs*27 (F521Sfs*27) and
p.G538Efs*30 (G519Efs*30). Variant p.F540Sfs*27 was identiﬁed by the presence of a
single new tryptic peptide, p.543-557 LSLGAQNLASSQIQR (underlined), whereas the
p.G538Efs*30 variant was identiﬁed by the presence of 3 new tryptic peptides:
TFPGFFSPMLESLSVR, LSLGAQNLASSQIQR, and NPVLITLG, covering p.528-566. The
location, in the WT protein, of the 5 amyloidogenic variants identiﬁed in patients 1–5 is
shown in bold: p.G538Efs*30, p.F540Sfs*27, p.E543K, p.E545K, and p.G574F.
466G519Efs*30 (p.G538E*30) was identiﬁed in patient 3 by
the presence of 3 new tryptic peptides:
FPGFFSPMLESLSVR, MH2þ m/z 907.96; LSLGAQN-
LASSQIQR, MH2þ m/z 793.44; and NPVLITLG, MH2þ
m/z 413.76 (Table 1). WT FibA peptide fragment p.548-
599 was also identiﬁed in patient 3.
It is not known whether the source of the WT
ﬁbrinogen in the samples from patients 3 to 5 was
blood contamination of the biopsy specimens or
whether WT ﬁbrinogen was incorporated into the
amyloid.
DISCUSSION
Fibrinogen is a 340-kD plasma protein synthesized by
hepatocytes and is essential for blood coagulation. It is
composed of 2 sets of 3 subunits: alpha, beta, and
gamma. The alpha subunit is the largest of the three
and is encoded by the FGA gene, located on chromo-
some 4. Mutations in this gene have been linked toKidney International Reports (2017) 2, 461–469
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orders of variable severity such as aﬁbrinogenemia,
dysﬁbrinogenemia, and hypoﬁbrinogenemia.
AFib amyloidosis is an autosomal dominant disease,
ﬁrst described in 1993 among members of a Peruvian
kindred who were heterozygous for the R554L substi-
tution.3 Interestingly, subject 6 described in the cur-
rent study also had substitution of an arginine residue
at position 554 (R554H), but unlike the R554L, it was
not associated with renal amyloid in our patient. The
likely explanation is that both arginine and histidine
amino acids are hydrophilic, and thus the substitution
may not necessarily induce a signiﬁcant change in the
protein structure. Leucine, by contrast, is hydrophobic
and a replacement of arginine with leucine might have
more profound effects on the protein conformation.
Bone marrow examination of patient 6 revealed low-
level clonal plasma cells, and the SAP scan showed
extensive bone uptake, strongly suggesting AL
amyloidosis (data not shown). LMD and LC-MS/MS
examination of the renal biopsy showed kappa light
chain deposits that further validated the diagnosis of
systemic AL amyloidosis, subsequently conﬁrmed by
regression of amyloid and reduction of proteinuria after
successful chemotherapy.
To date, 9 FGA variants have been identiﬁed in
different kindreds (http://www.amyloidosismutations.
com), and although the precise mechanism that pro-
motes amyloid ﬁbril formation in this disease is not
fully understood, it has been shown that all mutations
are clustered within close proximity in the 50 end of
exon 5 of the FGA gene and the amyloidogenic ﬁbril
subunit consists of residues 500–580.6 Here we report 5
patients with novel FGA mutations G555F, F521Sfs*27,
G519Efs*30, E526K, and E524K as the cause of their
renal amyloidosis. To our knowledge, the patients with
the FGA G555F and F521Sfs*27 mutations are the ﬁrst
cases of AFib amyloidosis described in Scandinavia.
None of these patients had an inﬂammatory disease; the
inﬂammatory markers C reactive protein and serum
amyloid A protein were within normal range. Nor did
they have evidence of a plasma cell dyscrasia, to sug-
gest amyloid A (AA) amyloidosis or AL amyloidosis.
Analysis of other genes associated with hereditary
renal amyloidosis in all 5 cases revealed no mutations.
Interestingly, only 1 patient had a family history of
kidney disease. This is consistent with the known
variable disease penetrance in AFib amyloidosis, pre-
viously highlighted among subjects with E526V
variant, the most common cause of hereditary renal
amyloidosis in the United Kingdom.33 In our cohort,
the diagnosis of AFib amyloidosis was made on kidney
biopsy using a combination of immunohistochemistry
and LMD and LC-MS/MS, in conjunction with geneticKidney International Reports (2017) 2, 461–469analysis. The renal histological appearance in all 5 pa-
tients was identical to that associated with all previ-
ously reported amyloidogenic FGA variants with
characteristic massive glomerular amyloid in the
absence of extraglomerular deposits. Interestingly, the
kidney biopsy of patient 5 revealed the presence of
characteristic glomerular ﬁbrinogen amyloid deposits
and crescentic glomerulonephritis, the latter in associ-
ation with high titer anti-GBM antibodies. This pa-
tient’s renal function declined rapidly to ESRD,
suggesting a major contribution to the clinical pheno-
type from the anti-GBM disease. To our knowledge, he
is the ﬁrst case diagnosed with both the AFib
amyloidosis and anti-GBM antibody disease; the nature
of this association is unclear.
To date, 4 frameshift mutations in the FGA gene
have been reported and all were associated with an
early disease onset and a very aggressive phenotype
quickly progressing to ESRD: M517_F521delinsQSfs*28
was identiﬁed in a Korean girl who presented at 7 years
of age;34 V522Afs*27 was found in a French kindred
with the index patient and his son presenting at the age
of 31 and 12 years, respectively;6 E524Efs*25 was
associated with a renal failure resulting in death in the
fourth decade in an American kindred;5 and
T525Tfs*24 was identiﬁed in a Chinese subject who
presented in early thirties.33 Patients 2 and 3 described
here, with the F521Sfs*27 and G519Efs*30 frameshift
mutations, presented at the age of 30 and 45 years,
respectively, and their renal function deteriorated more
rapidly than in subjects who had a single base substi-
tution. From this and previous reports, we have
established a signiﬁcant difference in the age at onset
among patients who were diagnosed with frameshift
mutations (median age 30 years) and those who had
single amino acid substitutions (median age 59 years),
P ¼ 0.0001 (Figure 3). The sequence of all ﬁbrinogen A
alpha chain peptides arising from the frameshift mu-
tations is a hybrid between a short fragment of normal
sequence and a completely new C-terminal peptide.
Remarkably, the novel C terminal has, in all cases, an
almost identical amino acid sequence that terminates
prematurely at position 548 instead of the 610 for the
WT mature protein.6 It is notable that there was evi-
dence of the WT protein fragment within the samples
of patients 3 to 5, contrasting previous reports that
identiﬁed only variant ﬁbrinogen within the amyloid
deposits. It is possible that WT ﬁbrinogen was derived
from blood contamination in these samples that is
supported by the additional presence of Fib beta and
gamma chains, although one cannot exclude the pos-
sibility that these particular novel variants somehow
promote the incorporation of the WT protein into
amyloid.467
Figure 3. Age at disease onset in patients with AFib amyloidosis.
Patients with AFib amyloidosis caused by frameshift mutations
(n ¼ 6) in the FGA gene had earlier disease onset than subjects
with a single amino acid substitution (n ¼ 70) (Mann-Whitney test,
P < 0.0001). AFib, fibrinogen A alpha chain.
TRANSLATIONAL RESEARCH D Rowczenio et al.: Fibrinogen A Alpha Chain AmyloidosisThe treatment of AFib amyloidosis includes sup-
portive measures and for those with ESRD consider-
ation of kidney transplantation. However, because of
the recurrence of amyloid in the renal allograft,
combined liver and kidney transplantation, which
replaces the source of circulating amyloidogenic
ﬁbrinogen with the WT (nonamyloidogenic) protein
and thus prevents ongoing amyloid deposition in the
renal allograft or elsewhere, can be considered
although the procedural risk is high.35 Consideration
of liver and kidney transplantation may be of even
more relevance in patients with AFib due to frame-
shift mutations, given the aggressive and early onset
nature of their disease. This study highlights the
importance of deﬁnitive characterization of the am-
yloid ﬁbril protein in all cases of systemic amyloid-
osis, to avoid misdiagnosis and administration of
inappropriate and potentially harmful therapy,36
while also highlighting some of the complexities in
diagnosis that often require combined genetic anal-
ysis, immunohistochemistry, and LMD and LC-MS/
MS.
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